Abeona Therapeutics (STU:PCJ) Cash Flow for Dividends: €0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PCJ Abeona Therapeutics Inc STU:PCJ
51 GF Score
Price €6.23
GF Value €15.12
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Abeona Therapeutics Cash Flow for Dividends?

Abeona Therapeutics STU:PCJ +4.32% 51 Cash Flow for Dividends is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:PCJ with a GF Score™ of 51/100 and a GF Value™ of €15.12 (Possible Value Trap). The stock has 8 warning signs investors should review.

Abeona Therapeutics's cash flow for dividends for the three months ended in Mar. 2026 was €0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Abeona Therapeutics Cash Flow for Dividends Related Terms

Abeona Therapeutics Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Abeona Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abeona Therapeutics Cash Flow for Dividends Chart

Abeona Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Abeona Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:PCJ
51GF Score
Abeona Therapeutics Inc STU:PCJ
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abeona Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €0.00 Mil mean?
Abeona Therapeutics (STU:PCJ) has a Cash Flow for Dividends of €0.00 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Abeona Therapeutics and its competitors.
Is Abeona Therapeutics' Cash Flow for Dividends too high?
Abeona Therapeutics' current Cash Flow for Dividends is €0.00 Mil. Overall, Abeona Therapeutics has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' Cash Flow for Dividends compare to RCKT and UPB?
Abeona Therapeutics' Cash Flow for Dividends of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Abeona Therapeutics and its competitors. Abeona Therapeutics's current Cash Flow for Dividends is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Abeona Therapeutics (STU:PCJ) is currently considered Possible Value Trap. The stock's GF Value™ is €15.12, compared to a current price of €6.23 — trading 58.8% below its estimated fair value. The current Cash Flow for Dividends is €0.00 Mil. Abeona Therapeutics' overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Abeona Therapeutics (STU:PCJ), the current Cash Flow for Dividends is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abeona Therapeutics (STU:PCJ) Overvalued in 2026?

Based on GuruFocus' analysis, Abeona Therapeutics stock appears to be undervalued. The current stock price of €6.23 is trading 58.8% below its estimated GF Value™ of €15.12. GuruFocus considers Abeona Therapeutics to be Possible Value Trap.

Key valuation signals for STU:PCJ:

  • Cash Flow for Dividends: €0.00 Mil
  • GF Value™: €15.12 vs. price of €6.23 (58.8% below fair value)
  • GF Score™: 51/100 with 8 warning signs

No single metric tells the full story. See the STU:PCJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abeona Therapeutics Business Description

Other Exchanges ABEO:USA0H7R:UK
Address 6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
51GF Score

Get the complete analysis for STU:PCJ

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.23
Price
€15.12
GF Value